Retifanlimab vs Avelumab in Metastatic Merkel Cell Carcinoma: New Comparative Data
A new comparative analysis puts retifanlimab and avelumab side by side in metastatic Merkel cell carcinoma, sharpening first-line systemic therapy choices in this rare skin cancer.